Therapy-related myelodysplastic syndrome: Morphologic subclassification may not be clinically relevant

American Journal of Clinical Pathology

Volumn 127, Issue 2, 2007, Pages 197-205

  Singh, Zeba N ^a   Huo, Dezheng ^a   Anastasi, John ^a   Smith, Sonali M ^a   Karrison, Theodore ^a   Le Beau, Michelle M ^a   Larson, Richard A ^a   Vardiman, James W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Therapy related leukemia; Therapy related myelodysplasia; World Health Organization classification

Indexed keywords

ARTICLE; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MORPHOLOGICAL TRAIT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; WORLD HEALTH ORGANIZATION; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; CHROMOSOME ABERRATION; CLASSIFICATION; MYELOID LEUKEMIA; PATHOLOGY; RISK; SURVIVAL;

ANTINEOPLASTIC AGENT;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; HUMANS; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK; SURVIVAL ANALYSIS;

EID: 33847061341     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/NQ3PMV4U8YV39JWJ     Document Type: Article

References (36)

1. Foucar K, Langdon RM II, Armitage JO, et al. Myelodysplastic syndromes: a clinical and pathologic analysis of 109 cases. Cancer. 1985;56:553-561.
2. Kerkhofs H, Hermanns J, Haak HL, et al. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol. 1987;65:73-81.
3. Economopoulos T, Stathakis N, Foudoulakis A, et al. Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification. Eur J Haematol. 1987;38:338-344.
4. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983-992.
5. Howe RB, Porwit-MacDonald A, Wanat R, et al. The WHO Classification of MDS does make a difference. Blood. 2004;103:3265-3270.
6. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594-7603.
7. Bennett JM, Catovsky D, Daniel MT, et al. French-American-British (FAB) co-operative group: proposals for the classification of myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
8. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620-625.
9. Brunning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:63-73. World Health Organization Classification of Tumours.
10. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
11. Vardiman JW, Golomb HM, Rowley JD, et al. Acute non-lymphocytic leukemia in malignant lymphoma: a morphological study. Cancer. 1978;42:229-242.
12. Smit CGS, Meyler L. Acute myeloid leukaemia after treatment with cytostatic agents. Lancet. 1970;2:671-672.
13. Cardamone JM, Kimmerle RI, Marshall EY. Development of acute erythroleukemia in B-cell immunoproliferative disorders after prolonged therapy with alkylating agents. Am J Med. 1974;57:836-842.
14. Rappaport AH, Cohen RJ, Castro JR. Erythroleukemia following total-body radiation for advanced lymphocytic lymphoma. Radiology. 1975;115:179-180.
15. Steigbigel RT, Kim H, Potolsky A, et al. Acute myeloproliferative disorder following long-term chlorambucil therapy. Arch Intern Med. 1974;134:728-731.
16. Foucar K, McKenna RN, Bloomfield CD, et al. Therapy-related leukemia: a panmyelosis. Cancer. 1979;43:1285-1296.
17. Khaleeli M, Keane WM, Lee GR. Sideroblastic anemia in multiple myeloma: a preleukemic change. Blood. 1973;41:17-25.
18. Fisher WB, Armentrout SA, Weisman R Jr, et al. "Preleukemia": a myelodysplastic syndrome often terminating in acute leukemia. Arch Intern Med. 1973;132:226-232.
19. Michels SD, McKenna RW, Arthur DC, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphological study of 65 cases. Blood. 1985;65:1364-1372.
20. Selby P, Horwich A. Secondary leukaemia in Hodgkin's disease [letter]. Lancet. 1986;1:1027-1028.
21. Brusamolino E, Papa G, Valagussa P, et al. Treatment-related leukemia in Hodgkin's disease: a multi-institution study on 75 cases. Hematol Oncol. 1987;5:83-98.
22. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440.
23. Kroger N, Brand R, van Biezen A, et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2006;37:183-189.
24. Raza A, Lisak L, Billmeier J, et al. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. Leuk Lymphoma. 2006;47:433-440.
25. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102:43-52.
26. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley and Sons; 1980.
27. Matsuda A, Jinnai I, Yagasaki F, et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia. 1998;12:482-485.
28. Rosati S, Mick R, Xu F, et al. Refractory cytopenia with multilineage dysplasia: further characterization of an ~"unclassifiable" myelodysplastic syndrome. Leukemia. 1996;10:20-26.
29. Kantarjian HM, Keating MJ, Walters RS, et al. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986;4:1748-1757.
30. Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Therapy-related myelodysplasia and acute myeloid leukemia: cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia. 1993;7:1975-1986.
31. Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia. 2002;16:2366-2378.
32. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997;89:3323-3329.
33. Grimwade D, Walker H, Oliver F, et al, for the Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
34. Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18:120-125.
35. Ballen KK, Gilliland DG, Guinan EC, et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 1997;20:737-743.
36. Witherspoon RP, Deeg HJ, Storer B, et al. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. J Clin Oncol. 2001;19:2134-2141.